Skip to main navigation Skip to search Skip to main content

A Phase Iii, Multicenter, Randomized Study Of Atezolizumab (Anti−Pdl1 Antibody) In Combination With Enzalutamide Versus Enzalutamide Alone In Patients With Metastatic Castrationresistant Prostate Cancer After Failure Of An Androgen Synthesis Inhibitor And Failure Of, Ineligibility For, Or Refusal Of A Taxane Regimen

Project: Research

Project Details

Project Description

NMA HREC Reference Number: HREC/16/MonH/420
Monash Health Ref: 17-0000-042A
StatusFinished
Effective start/end date20/05/19 → 19/05/24

Keywords

  • clinical trial
  • treatment efficacy
  • prostate cancer

Clinical Trial Phase

  • Phase III (a & b)